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ABSTRACT
Introduction: Central nervous system toxicity
is a well-known side effect of isotretinoin
treatment. The aim of this study was to
establish the effects of isotretinoin on retinal
nerve fiber layer (RNFL) thickness.
Materials and Methods: Study subjects received
oral isotretinoin treatment for nodulocystic acne.
All patients underwent a detailed ophthalmologic
examination including best-corrected visual
acuity, slit-lamp examination, tonometry, color
vision assessment, fundoscopy, and RNFL
measurement. RNFL measurements by optical
coherence tomography were done at onset, and
were repeated at the 1st and 6th months of
therapy.
Results: A total of 22 eyes of 11 patients (seven
males and four females) were included in this
study. The mean age of the patients was
20.18 ± 5.13 (14–26) years. Mean RNFL
thickness was 90.72 ± 9.19 (78.2–112.0) lm
before treatment, 90.40 ± 9.24 (79.5–112.4) lm
after 1 month of treatment, and 90.52 ± 8.92
(78.4–114.8) lm after 6 months. No statistically
significant change was detected between RNFL
thickness values before and after treatment.
Conclusion: No adverse effects of systemic
isotretinoin treatment on RNFL thickness were
observed.
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INTRODUCTION
Isotretinoin, or 13-cis retinoic acid, is the
treatment of choice for severe recalcitrant
nodular acne, and has been used to treat
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various other skin disorders, such as severe
recalcitrant psoriasis, for almost two decades
[1]. This drug has numerous ocular side effects,
including abnormal meibomian gland
secretions, blepharoconjunctivitis, corneal
opacities, decreased dark adaptation, decreased
tolerance to contact lens use, decreased vision,
increased tear osmolarity, keratitis, meibomian
gland atrophy, myopia, ocular discomfort, dry
eyes, photophobia, and teratogenic ocular
abnormalities [2–4].
Previous reports have suggested a causal
association between oral isotretinoin and
acquired central nervous system (CNS)
neurotoxicity and neuropathy [5–7]. The most
frequent CNS adverse effect associated with oral
isotretinoin is headache, either as an
independent adverse effect or as part of benign
intracranial hypertension, which is additionally
characterized by nausea and visual changes
[5–7]. A single case of optic swelling associated
with isotretinoin has also been reported [8].
Retinal ganglion cells contain melanopsin,
which is very similar to other opsin
photopigments, and it is known that
melanopsin uses the same retinaldehyde
chromophore. Therefore, isotretinoin may
exert an inhibitory effect on chromophore
regeneration in retinal ganglion cells similar to
what is seen in rod and cone cells [9]. However,
to the best of the authors’ knowledge, this is the
first study that objectively determines retinal
nerve fiber layer (RNFL) thickness changes after
6 months of oral isotretinoin treatment.
MATERIALS AND METHODS
Patients prescribed typical oral isotretinoin
(0.5 mg/kg) to treat nodulocystic acne were
referred by dermatologists for a detailed
ophthalmologic examination. Informed consent
and ethical approval was given by patients.
This initial examination included visual acuity,
slit-lamp examination, tonometry, color vision
assessment with Ishihara plates, dilated
fundoscopy with a 78D lens, and RNFL
measurement by Optical Coherence
Tomography (Cirrus HD Spectral OCT, Carl Zeiss
Meditec Inc., Dublin, CA, USA). Patients
[40 years of age, with systemic and/or ocular
disorders, those who had previous ocular surgery,
and those receiving systemic corticosteroid
treatment were excluded. Best-corrected visual
acuity (BCVA) of all patients was measured by
Snellen chart at 6 m prior to isotretinoin
treatment. The same experienced observer
performed RNFL thickness measurements by
Optical Coherence Tomography at the onset of
isotretinoin treatment, as well as after the 1st and
6th months of therapy. Three consecutive
measurements were acquired at each visit, and
the mean of these three readings was used for
statistical analysis. All statistical analyses were
performed using SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA) and a P value \0.05 was
considered statistically significant.
RESULTS
A total of 22 eyes of 11 patients (seven males and
four females) were included in this study. The
mean age of the patients was 20.18 ± 5.13
(14–26) years. BCVA of all patients was 20/20 by
Snellen chart at 6 m prior to isotretinoin
treatment. BCVA and refraction values showed
no significant change after 1 or 6 months of
treatment. Mean intraocular pressure was
13.2 ± 1.4 mmHg at onset, 13.7 ± 1.5 mmHg at
1-month follow-up, and 13.4 ± 1.2 mmHg at
6 months. No change was detected in color
vision or fundoscopy before and after treatment.
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Mean RNFL thickness was 90.72 ± 9.19
(78.2–112.0) lm before treatment, 90.40 ± 9.24
(79.5–112.4) lm at 1 month, and 90.52 ± 8.92
(78.4–114.8) lm at 6 months. No statistically
significant change was detected in RNFL
thickness values before and after treatment
(P = 0.08). There were no consistent trends of
change in the regional areas of thickness, which is
shown in a double-hump pattern in printouts.
DISCUSSION
Retinoids are believed to play an essential role in
the growth, differentiation, and function of
nervous tissue in vivo and in vitro.
Electrophysiological and clinical findings have
suggested a causal association between an
acquired CNS neurotoxicity or neuropathy and
oral retinoids [10–12]. Decreased visual acuity,
various visual field defects, pseudotumor cerebri,
optic neuritis, and decreased color vision are the
most common side effects involving the ocular
nervous system that have been shown to be
closely related to oral isotretinoin therapy [1, 3,
13, 14]. Visual field defects are more common in
the central visual field due to pseudotumor
cerebri and/or optic neuropathy [15]. In
addition, oral retinoids have multiple
mucocutaneous and systemic side effects.
Different retinoids have different side effect
profiles: isotretinoin tends to cause more
mucosal drying, acitretin has higher incidences
of alopecia and palmar/plantar desquamation,
and reduced night vision is more common with
fenretinide [16]. Teratogenicity is also a limiting
factor with all oral retinoids.
Several studies have reported the importance
of RNFL thickness determination in the early
diagnosis and management of optic nerve
conditions, such as glaucoma, and optic nerve
diseases, including optic neuritis [17]. Optical
coherence tomography can reveal changes in
RNFL thickness before visual field defects appear
[18]. In the present study, the authors did not
find any RNFL changes due to isotretinoin
treatment, despite the fact that oral isotretinoin
treatment has been known to cause decreased
dark adaptation, pseudotumor cerebri, optic
nerve edema, and headaches. However, Dinc
et al. [19] reported a case of bilateral optic nerve
atrophy and decreased RNFL thickness associated
with isotretinoin treatment for acne vulgaris,
supporting the hypothesis that isotretinoin may
cause RNFL changes.
In the present study, no neurotoxic side
effects were detected. Similar to the present
findings, Sari et al. [15] evaluated optic nerve
function in patients treated with oral
isotretinoin both clinically and with visual
field tests, and reported no significant change
after 5.5 months. In a pivotal study by Weleber
et al. [4], three of 50 patients treated with
isotretinoin (1 mg/kg/day) for cystic acne
complained of poor night vision and/or
excessive glare sensitivity. While still receiving
the drug or shortly thereafter, two patients were
found to have abnormal dark-adaptation
curves, with elevations of either cone or rod
thresholds, or both. Six months following
cessation of therapy, the electroretinograph
was still abnormal for one patient, but
continued improvement was evident at
25 months; for the second patient, the
electroretinograph was normal at 1 year.
Nyctalopia, or night blindness, has been
reported with isotretinoin use [20]. This has
been associated with objectively abnormal
scotopic electroretinograms. It has been
postulated that competitive inhibition of
ocular retinol dehydrogenase by isotretinoin
may be the cause of the nyctalopia [21, 22].
None of the patients in this study developed
nyctalopia after 6 months of treatment.
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In the present study, the authors did not find
any color vision disturbances. Color vision is a
sensitive indicator of optic nerve dysfunction. It
is reduced in retinal and optic nerve disorders.
Fraunfelder et al. [2] first suggested an
association between isotretinoin and reversible
decreased color vision.
There are limitations of this study that must
be addressed. First, the authors did not perform
any electrophysiological studies. In a recent
study, an increased latency of P100 wave was
detected after therapy in 18% of patients treated
orally with isotretinoin [10]. Although this result
was not statistically significant, subclinical
effects of isotretinoin on optic nerve functions,
which can be detected electrophysiologically
before anatomical signs occur, may be possible.
In addition, assessment of pupillary functions
without using pupillography was another
limitation of the present study.
CONCLUSION
In conclusion, the authors did not find any
adverse effects of systemic isotretinoin
treatment on RNFL thickness. Nevertheless,
the authors think that the assessment of
these functions in a larger patient group and
with additional tests for early detection of
visual field loss, such as Short Wavelength
Automated Perimetry (SWAP) or Frequency
Doubling Technology (FDT), would be more
appropriate.
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